Guardant Health, Inc. (NASDAQ: GH)

Guardant Health, Inc., often referred to as Guardant Health, is a company that operates in the precision oncology industry. Its primary focus is on the development and commercialization of innovative liquid biopsy tests that are designed to improve cancer diagnosis, treatment, and management. The company's stock symbol is GH.

Guardant Health's main business activities involve the provision of liquid biopsy tests that enable the detection of cancer biomarkers in blood or other bodily fluids. The company operates in the precision oncology industry, which is a sector that is dedicated to improving cancer care through the use of advanced technologies. Guardant Health's operations span across various countries and regions, including the United States and Europe.

The company generates revenue primarily through the sale of its liquid biopsy tests to biopharmaceutical companies, academic research institutions, and clinical laboratories. Guardant Health's customers include leading biopharmaceutical companies such as Roche, AstraZeneca, and Merck, as well as top-ranked academic research institutions and clinical laboratories.

The Guardant360 CDx test is one of the company's primary products. It is a comprehensive liquid biopsy test that provides tumor mutation profiling to help identify patients with advanced cancer who may benefit from targeted therapies. The test is approved by the FDA and has been used as a companion diagnostic in clinical trials for several cancer therapies, including TAGRISSO (osimertinib), RYBREVANT (amivantamab-vjmw), LUMAKRAS (sotorasib), and ENHERTU (fam-trastuzumab deruxtecan-nxki).

Another product offered by Guardant Health is the Shield test. It is a blood-based test designed to detect colorectal cancer signals in the bloodstream. The test uses a novel multimodal approach to detect DNA shed by tumors and has been shown to have high sensitivity and specificity in detecting colorectal cancer. Guardant Health has submitted a premarket approval application (PMA) to the FDA for the Shield test and expects to expand its use to detect lung and multi-cancer screening in the future.

In addition to its testing services, Guardant Health offers several biopharmaceutical products and services. These include the GuardantOMNI test, which covers over 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. The company also offers the GuardantINFINITY test, a next-generation smart liquid biopsy test that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response.

Guardant Health is a leading precision oncology company, with a strong presence in the industry. The company's liquid biopsy tests are used by leading biopharmaceutical companies and academic research institutions, and its products have been approved by regulatory authorities in the United States and Europe. The company's competitive advantages include its proprietary digital sequencing technology, its comprehensive genomic profiling tests, and its ability to detect genetic mutations and other biomarkers associated with cancer. Guardant Health's tests are also designed to be non-invasive and can be used to monitor cancer patients over time, which can help to improve patient outcomes and reduce healthcare costs.

Guardant Health's brand names and/or trade names of its products and services include the Guardant360 CDx test, Guardant360 LDT test, Guardant Reveal test, Shield test, GuardantOMNI test, and GuardantINFINITY test.